NCT02126553View on ClinicalTrials.gov

Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 13, 2014

Primary Completion Date

November 30, 2021

Study Completion Date

November 30, 2021

Conditions
Alkylating Agent-Related Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02126553 - Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission | Biotech Hunter | Biotech Hunter